NEWS
2021.3.4
The article introducing Rebirthel was published in the web magazine “Nikkei Biotechnology & Business”
Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its ...
NEWS
2020.12.11
Our R&D activity to develop a new T cell therapy for the novel coronavirus infection was introduced on Japanese TV program.
Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the col...
NEWS
2020.10.15
Collaborative research project between Rebirthel and Fujita Health University – On-side visit video
This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Fr...
NEWS
2020.10.14
Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –
Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to deve...
NEWS
2020.10.1
Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.
Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka ...
NEWS
2020.4.9
Introduction
The world is presently facing the serious situation of the coronavirus pandemic. We all need to...